Key statistics
As of last trade Fagron NV (0HNZ:LSE) traded at 22.30, -6.30% below its 52-week high of 23.80, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.15 |
|---|---|
| High | 22.30 |
| Low | 22.30 |
| Bid | 21.55 |
| Offer | 22.65 |
| Previous close | 22.45 |
| Average volume | 21.74k |
|---|---|
| Shares outstanding | 73.67m |
| Free float | 56.70m |
| P/E (TTM) | -- |
| Market cap | 1.66bn EUR |
| EPS (TTM) | -- |
| Annual div (ADY) | 0.35 EUR |
|---|---|
| Annual div yield (ADY) | 1.56% |
| Div ex-date | May 19 2025 |
| Div pay-date | May 21 2025 |
Data delayed at least 20 minutes, as of Mar 03 2026 14:03 GMT.
More ▼
Announcements
- Fagron completes acquisition of Vepakum
- Fagron voltooit overname van Vepakum
- Disclosure of a transparency notification from AOC Pharma S.à r.l.
- Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l.
- Fagron voltooit strategische overname van Pharmavit Europe en versterkt daarmee haar leiderschap in snelgroeiende nutraceutische ingrediënten in EMEA
- Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA
- Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA
- Fagron behoudt uitstekende prestaties in boekjaar 2025 met 9,2% omzetgroei en een stijging van de REBITDA met 10,9%
- Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary
- Fagron verkrijgt goedkeuring van lokale autoriteiten voor de overname van Vepakum in Brazilië en rondt de overname van Magilab in Hongarije af
More ▼
